Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Therapeutics save search
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE 4 | $42.16 1.35% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
SWTX | $42.48 -3.7% -3.84% 810K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
first report therapeutics financial results
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-04-18 (Crawled : 05:00) - globenewswire.com
ADXN | $24.01 9.14% 8.37% 19K
|
Health Technology
| Email alert
Add to watchlist
year update therapeutics financial results
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Published: 2024-04-17 (Crawled : 20:00) - prnewswire.com
LGND | News | $72.61 -7.94% -8.62% 130K
|
Health Technology
| Email alert
Add to watchlist
VKTX | News | $64.7 -2.66% -2.74% 2.4M
|
Health Technology
| Email alert
Add to watchlist
first report for therapeutics financial results
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
GTHX | News | $4.16 -2.8% -2.88% 690K
|
Health Technology
|
| O: 1.72%
H: 4.82%
C: 3.13%
first therapeutics financial results
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
WINT | News | $0.3399 -15.3% -18.06% 1.8M
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
business key therapeutics financial results
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ALRN | $5.01 17.88% 15.17% 1.8M
|
Health Technology
|
| O: -9.95%
H: 3.18%
C: 0.19%
business year update therapeutics financial results
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PTCT | News | $24.71 -1.79% -1.82% 820K
|
Health Technology
|
| O: 2.01%
H: 1.35%
C: -0.18%
first conference therapeutics financial results
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: 2.37%
H: 0.9%
C: -0.54%
first report therapeutics financial results
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
ADXN | $24.01 9.14% 8.37% 19K
|
Health Technology
|
| O: -6.31%
H: 2.47%
C: 2.47%
conference therapeutics financial results
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CYTO | $1.48 -7.95% 23K
|
Manufacturing
|
| O: -5.56%
H: 7.49%
C: 6.95%
business year therapeutics financial results
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: -2.66%
H: 1.26%
C: 0.37%
first report therapeutics financial results
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
NRIX 1 d | $14.43 2.49% 2.43% 970K
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
first update therapeutics financial results
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.94 -1.24% -1.26% 710K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
HOWL | $5.87 0.51% 0.51% 120K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
wtx-518 preclinical meeting therapeutics results
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
CYTO | $1.48 -7.95% 23K
|
Manufacturing
|
| O: 4.21%
H: 5.56%
C: 5.56%
business year update therapeutics financial results
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.775 -6.09% -6.48% 140K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.